Breaking the “Untreatable”: Biostar Pharma’s UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
SAN FRANCISCO, Dec. 16, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 2563.HK), today announced that the first patient has been dosed for one of its key oversea clinical studies: the U.S. pivotal clinical study (NCT06764940) of Utidelone Injection(UTD1) combined with capecitabine for the treatment of HER2-negative breast cancer brain...
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials The financing will support continued development of ADC and multi-specific antibody platforms aimed at addressing...
Perennial Healthcare City Launched Adjacent to Chongqing East HSR Station, Western China’s Largest HSR Hub
Establishment of new healthcare gateway in Chongqing amid the 10th anniversary of the Chongqing Connectivity Initiative and as part of the 35th anniversary celebration of Singapore-China diplomatic relations; Maiden investment in Chongqing marks Perennial Holdings' sixth healthcare-centric TOD, further strengthening its footprint in China SINGAPORE, Dec. 16, 2025 /PRNewswire/ -- Perennial...
Enginprime Medical Inc Announces First-in-Human Study of Its Leading OpusOne™ pVAD
HANGZHOU, China, Dec. 16, 2025 /PRNewswire/ -- Enginprime Medical Inc ("Enginprime"), an emerging leader in percutaneous ventricular assist device (pVAD) technologies and a Voyagers Capital portfolio company, today announced that its industry leading pVAD, OpusOne™, has entered its first-in-human clinical study at The Second Affiliated Hospital, School of Medicine, Zhejiang University ("SAHZU"). This milestone marks the first clinical evaluation...
Miroma Project Factory: Powers Clinical-Grade App for One of Australia’s Largest Smoking Cessation Trials
SYDNEY, Dec. 16, 2025 /PRNewswire/ -- Miroma Project Factory (MPF) has delivered a bespoke mobile solution for Screen2Quit, part of the International Lung Study trial and one of Australia's most ambitious research studies targeting smoking cessation in people undergoing lung cancer screening. Screen2Quit by Miroma Project Factory: powering Australia’s largest smoking cessation trial with...
HitGen Submits Commitment Letter to Science Based Targets initiative (SBTi)
CHENGDU, China, Dec. 15, 2025 /PRNewswire/ -- HitGen Inc. (hereinafter referred to as "HitGen", SSE: 688222.SH), announced it has officially submitted its commitment letter to the Science Based Targets initiative (SBTi). HitGen has pledged to set near-term science-based targets within the next two years, aligned with the SBTi's stringent criteria. This...
PM-International expands child sponsorships to 8,000 with €2.88 million donation
SCHENGEN, Luxembourg, Dec. 15, 2025 /PRNewswire/ -- Global support for children in need is declining rapidly. According to World Vision, governments and institutions worldwide have cut funding for children's aid by $16.3 billion, limiting access to food, healthcare and education for millions of vulnerable children. At the same time, PM-International is expanding its commitment through its charity Foundation PM...
NYSE Content Advisory: Pre-Market Update + Seven of the Top 10 IPOs in 2025 List on NYSE
NEW YORK, Dec. 15, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on December 15th Stocks are fractionally higher early Monday as a busy week of economic data begins,...
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a collaboration with Daiichi Sankyo...
Neurabody Enters the UK Market with Selfridges Launch, Showcasing the Future of AI-Driven Ergonomics
LONDON, Dec. 15, 2025 /PRNewswire/ -- Neurabody, the AI-driven posture science company transforming modern ergonomics, today announced its official launch at Selfridges London, marking a significant milestone in the company's global expansion and consumer entry into the UK market. With this debut, Selfridges customers will experience NeuraSit, Neurabody's intelligent posture-support system that merges...
